Filling the gap in epidemiology, management and clinical course of COVID-19 vaccination-related pericarditis

Coronavirus disease 2019 (COVID-19) is responsible for the ongoing pandemic associated with significant morbidity and mortality around the globe.1,2 Vaccines based on a broad range of different technologies have proven highly effective at preventing symptomatic disease and death and have played an essential role in flattening the epidemiology curve.1,2 Nevertheless, some concerns have been raised due to rare cases of myocarditis and pericarditis following the receipt of COVID-19 vaccine, especially mRNA vaccines